Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 12/20 | 0.47 |
| ▸ | DHODH | Q02127 | 1/20 | 0.37 |
| ▸ | MAPK13 | O15264 | 4/20 | 0.37 |
| ▸ | MAPK12 | P53778 | 4/20 | 0.37 |
| ▸ | MAPK11 | Q15759 | 4/20 | 0.37 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.37 |
| ▸ | PRKD1 | Q15139 | 1/20 | 0.37 |
| ▸ | MET | P08581 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2891806 | 0.84 | MAPK14 (0.67) | MAPK14MAPK13MAPK12MAPK11MET | |
| SCHEMBL2891559 | 0.79 | MAPK14 (0.72) | MAPK14MAPK13MAPK12MAPK11PTGS2 | |
| SCHEMBL2883272 | 0.78 | MAPK14 (0.49) | MAPK14MAPK13MAPK12MAPK11PRKD1 | |
| SCHEMBL2891077 | 0.78 | MAPK14 (0.49) | MAPK14MAPK13MAPK12MAPK11PRKD1 | |
| SCHEMBL2888728 | 0.70 | MAPK14 (0.58) | MAPK14MAPK13MAPK12MAPK11PRKD1 | |
| SCHEMBL2889147 | 0.68 | MAPK14 (0.51) | MAPK14MAPK13MAPK12MAPK11PRKD1 | |
| SCHEMBL2787040 | 0.64 | MAPK14 (1.00) | MAPK14MAPK13MAPK12MAPK11MET | |
| SCHEMBL2947322 | 0.64 | BCL2L1 (0.39) | PTGS2 | |
| SCHEMBL2286610 | 0.64 | MAPK14 (0.82) | MAPK14MAPK13MAPK12MAPK11PTGS2 | |
| SCHEMBL284987 | 0.63 | MAPK14 (1.00) | MAPK14MAPK13MAPK12MAPK11PRKD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8084395-B2 | 4-aza indole derivatives and their use as fungicides | SYNGENTA CROP PROTECTION, INC. (US) | 2011-12-27 | — | — | US | disclosed |
| US-20100184598-A1 | 4-AZA INDOLE DERIVATIVES AND THEIR USE AS FUNGICIDES | SYNGENTA PARTICIPATIONS AG (CH) | 2010-07-22 | — | — | US | disclosed |
| EP-2136640-A2 | 4-AZA INDOLE DERIVATIVES AND THEIR USE AS FUNGICIDES | Syngeta Participations AG (CH) | 2009-12-30 | — | — | EP | disclosed |
| WO-2008132434-A2 | 4-AZA INDOLE DERIVATIVES AND THEIR USE AS FUNGICIDES | SYNGENTA PARTICIPATIONS AG (CH) | 2008-11-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100184598-A1 | 4-AZA INDOLE DERIVATIVES AND THEIR USE AS FUNGICIDES | IDO1, INMT, AZI2 | MAPK14 512/4885DHODH 329/4885MAPK13 1175/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.